Skip to main content
SpringerLink
Log in

DCIS and Hereditary Susceptibility for Breast Cancer

  • Chapter
  • First Online:
Ductal Carcinoma In Situ and Microinvasive/Borderline Breast Cancer

  • 1213 Accesses

Abstract

Ductal carcinoma in situ (DCIS) is a noninvasive, transformed, neoplastic lesion with a significant likelihood, but without certainty, of progressing to invasive breast cancer, although there are molecular and cellular features that have some predictive power for the development of invasive disease. In women who carry deleterious mutations in the BRCA or other genes, detection of DCIS is paramount, as these women are believed to be at much higher risk than sporadic cases for progressing to invasive cancer. Here, we discuss the state of knowledge of DCIS in the context of hereditary cancer syndromes and emphasize current recommendations for risk management.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Claus EB, Risch N, Thompson WD. Genetic analysis of breast cancer in the cancer and steroid hormone study. Am J Hum Genet. 1991;48(2):232–42.

    CAS  PubMed Central  PubMed  Google Scholar 

  2. Newman B, Austin MA, Lee M, King MC. Inheritance of human breast cancer: evidence for autosomal dominant transmission in high-risk families. Proc Natl Acad Sci U S A. 1988;85(9):3044–8.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  3. Foulkes WD. Inherited susceptibility to common cancers. N Engl J Med. 2008;359(20):2143–53.

    Article  CAS  PubMed  Google Scholar 

  4. Struewing JP. BRCA1 in special populations. Breast Dis. 1998;10(1–2):71–5.

    CAS  PubMed  Google Scholar 

  5. Wang F, Fang Q, Ge Z, Yu N, Xu S, Fan X. Common BRCA1 and BRCA2 mutations in breast cancer families: a meta-analysis from systematic review. Mol Biol Rep. 2012;39(3):2109–18.

    Article  CAS  PubMed  Google Scholar 

  6. Berry DA, Iversen ES Jr, Gudbjartsson DF, et al. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol. 2002;20(11):2701–12.

    Article  CAS  PubMed  Google Scholar 

  7. Lindor NM, Johnson KJ, Harvey H, et al. Predicting BRCA1 and BRCA2 gene mutation carriers: comparison of PENN II model to previous study. Fam Cancer. 2010;9(4):495–502.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  8. Antoniou AC, Hardy R, Walker L, et al. Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, myriad and the Manchester scoring system using data from UK genetics clinics. J Med Genet. 2008;45(7):425–31.

    Article  CAS  PubMed  Google Scholar 

  9. Claus EB, Petruzella S, Matloff E, Carter D. Prevalence of BRCA1 and BRCA2 mutations in women diagnosed with ductal carcinoma in situ. JAMA. 2005;293(8):964–9.

    Article  CAS  PubMed  Google Scholar 

  10. Trentham-Dietz A, Newcomb PA, Storer BE, Remington PL. Risk factors for carcinoma in situ of the breast. Cancer Epidemiol Biomarkers Prev. 2000;9(7):697–703.

    CAS  PubMed  Google Scholar 

  11. Claus EB, Stowe M, Carter D. Family history of breast and ovarian cancer and the risk of breast carcinoma in situ. Breast Cancer Res Treat. 2003;78(1):7–15.

    Article  CAS  PubMed  Google Scholar 

  12. Zhou W, Pan H, Liang M, et al. Family history and risk of ductal carcinoma in situ and triple negative breast cancer in a Han Chinese population: a case-control study. World J Surg Oncol. 2013. doi:10.11:248-7819-11-248.

    Google Scholar 

  13. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast cancer linkage consortium. Lancet. 1997;349(9064):1505–10.

    Google Scholar 

  14. Smith KL, Adank M, Kauff N, et al. BRCA mutations in women with ductal carcinoma in situ. Clin Cancer Res. 2007;13(14):4306–10.

    Article  CAS  PubMed  Google Scholar 

  15. Jacquemler J, Eisinger F, Guinebretiere JM, Stoppa-Lyonnet D, Sobol H. Intraductal component and BRCA1-associated breast cancer. Lancet. 1996;348(9034):1098.

    Article  CAS  PubMed  Google Scholar 

  16. Hoogerbrugge N, Bult P, de Widt-Levert LM, et al. High prevalence of premalignant lesions in prophylactically removed breasts from women at hereditary risk for breast cancer. J Clin Oncol. 2003;21(1):41–5.

    Article  CAS  PubMed  Google Scholar 

  17. Mazzola E, Cheng SC, Parmigiani G. The penetrance of ductal carcinoma in situ among BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 2013;137(1):315–8.

    Article  CAS  PubMed  Google Scholar 

  18. Bayraktar S, Elsayegh N, Gutierrez Barrera AM, et al. Predictive factors for BRCA1/BRCA2 mutations in women with ductal carcinoma in situ. Cancer. 2012;118(6):1515–22.

    Article  CAS  PubMed  Google Scholar 

  19. Hwang ES, McLennan JL, Moore DH, Crawford BB, Esserman LJ, Ziegler JL. Ductal carcinoma in situ in BRCA mutation carriers. J Clin Oncol. 2007;25(6):642–7.

    Article  PubMed  Google Scholar 

  20. van der Groep PD, van Diest PJ, Menko FH, Bart J, de Vries EG, van der Wall E. Molecular profile of ductal carcinoma in situ of the breast in BRCA1 and BRCA2 germline mutation carriers. J Clin Pathol. 2009;62(10):926–30.

    Article  PubMed  Google Scholar 

  21. van der Groep PD, Smolders YH, et al. HIF-1alpha overexpression in ductal carcinoma in situ of the breast in BRCA1 and BRCA2 mutation carriers. PLoS ONE. 2013;8(2):e56055.

    Article  PubMed Central  PubMed  Google Scholar 

  22. Masciari S, Dillon DA, Rath M, et al. Breast cancer phenotype in women with TP53 germline mutations: a li-fraumeni syndrome consortium effort. Breast Cancer Res Treat. 2012;133(3):1125–30.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  23. Franken B, de Groot MR, Mastboom WJ, et al. Circulating tumor cells, disease recurrence and survival in newly diagnosed breast cancer. Breast Cancer Res. 2012;14(5):R133.

    Article  PubMed Central  PubMed  Google Scholar 

  24. Kerlikowske K, Molinaro AM, Gauthier ML, et al. Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis. J Natl Cancer Inst. 2010;102(9):627–37.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  25. Rudloff U, Jacks LM, Goldberg JI, et al. Nomogram for predicting the risk of local recurrence after breast-conserving surgery for ductal carcinoma in situ. J Clin Oncol. 2010;28(23):3762–9.

    Article  PubMed  Google Scholar 

  26. Vasilatos SN, Broadwater G, Barry WT, et al. CpG island tumor suppressor promoter methylation in non-BRCA-associated early mammary carcinogenesis. Cancer Epidemiol Biomarkers Prev. 2009;18(3):901–14.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  27. Ibarra-Drendall C, Troch MM, Barry WT, et al. Pilot and feasibility study: prospective proteomic profiling of mammary epithelial cells from high-risk women provides evidence of activation of pro-survival pathways. Breast Cancer Res Treat. 2012;132(2):487–98.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  28. Kuhl C, Weigel S, Schrading S, et al. Prospective multicenter cohort study to refine management recommendations for women at elevated familial risk of breast cancer: the EVA trial. J Clin Oncol. 2010;28(9):1450–7.

    Article  PubMed  Google Scholar 

  29. King MC, Wieand S, Hale K, et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) breast cancer prevention trial. JAMA. 2001;286(18):2251–6.

    Article  CAS  PubMed  Google Scholar 

  30. Gronwald J, Tung N, Foulkes WD, et al. Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update. Int J Cancer. 2006;118(9):2281–4.

    Article  CAS  PubMed  Google Scholar 

  31. Gronwald J, Robidoux A, Kim-Sing C, et al. Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 2014;146(2):421–7.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported in part by the Breast Cancer Research Foundation (SDM), the Avon Foundation (SDM), the Debbie Strange-Browne Inflammatory Breast Cancer Foundation, and the Tempting Tables Organization (Muskegon, MI).

Author information

Authors and Affiliations

  1. Department of Internal Medicine and Epidemiology, University of Michigan Medical School and School of Public Health, University of Michigan Health System, Comprehensive Cancer Center, 1500 East Medical Center Drive, 48109, Ann Arbor, MI, USA

    Patrick G. Pilie MD

  2. Department of Internal Medicine, University of Michigan Health System, 1500 East Medical Center Drive, 48109, Ann Arbor, MI, USA

    Kara J. Milliron MS

  3. Department of Hematology Oncology, University of Michigan Health System, Comprehensive Cancer Center, 300 North Ingalls, 48109, Ann Arbor, MI, USA

    Sofia D. Merajver MD, PhD

Authors
  1. Patrick G. Pilie MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kara J. Milliron MS
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sofia D. Merajver MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sofia D. Merajver MD, PhD .

Editor information

Editors and Affiliations

  1. Comprehensive Cancer Center, University of Michigan Health System, Ann Arbor, Michigan, USA

    Lisa A. Newman

  2. Comprehensive Cancer Center, University of Michigan Health System, Ann Arbor, Michigan, USA

    Jessica M. Bensenhaver

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer Science+Business Media New York

About this chapter

Cite this chapter

Pilie, P., Milliron, K., Merajver, S. (2015). DCIS and Hereditary Susceptibility for Breast Cancer. In: Newman, L., Bensenhaver, J. (eds) Ductal Carcinoma In Situ and Microinvasive/Borderline Breast Cancer. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-2035-8_15

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-2035-8_15

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4939-2034-1

  • Online ISBN: 978-1-4939-2035-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation